ClinicalTrials.gg
RecruitingNCT03926338PICCUpdated Nov 20, 2025

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

A Phase 2 interventional study of Neoadjuvant toripalimab plus celecoxib for 6 cycles and Neoadjuvant toripalimab monotherapy for 6 cycles in Colorectal Cancer, Mismatch Repair-deficient (dMMR) and Microsatellite Instability-high (MSI-H), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing toripalimab in Colorectal Neoplasms — 10 open to participants now, 10 under way, none of them phase 3. toripalimab · Colorectal Neoplasms.

Planned enrollment
Largest of 16
270 · median 44
Started
2019
with 3 others
Phase 2
10 of 16
6 open now
Registered
3rd of 16
by date
Lead sponsor
5 of 16
Sun Yat-sen University

Among the 16 studies testing toripalimab in Colorectal Neoplasms, this one has the largest planned enrollment, is one of 4 that started in 2019, is one of 10 in phase 2, and was the 3rd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 16 studies testing toripalimab in Colorectal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing toripalimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Colorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer. Previous studies have found that colon cancer patients with dMMR/MSI-H cannot benefit from 5-fluorouracil (5-FU) adjuvant chemotherapy. Once patients have distant metastases, they are not sensitive to traditional palliative chemotherapy, and the prognosis is significantly worse than that of mismatch repair-proficient (pMMR)/microsatellite stability (MSS). A phase II clinical study of anti-PD-1 immunotherapy based on mismatch repair (MMR) status published in 《N Engl J Med》 showed that the objective response rate (ORR) of advanced colorectal cancer patients with dMMR received anti-PD-1 is 40%, and a longer response time can be obtained compared to conventional chemotherapy.

Anti-PD-1 neoadjuvant therapy has proven to be safe and feasible in lung cancer, bladder cancer and malignant melanoma, and can achieve more than 40% of major pathological response. However, there are no reports of anti-PD-1 neoadjuvant therapy for the dMMR/MSI-H colorectal cancer. Therefore, the aim of this study was to find the best multidisciplinary treatment for resectable colorectal cancer patient with the dMMR/MSI-H phenotype and to explore whether cyclooxygenase (COX) inhibitors combined with anti-PD-1 monoclonal antibody (mAb) could further improve efficacy.

Read the detailed description

The PICC trial is an investigator-initiated, multi-cohort platform trial designed to evaluate the efficacy and safety of neoadjuvant toripalimab, with or without celecoxib, in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer. Each cohort within the PICC platform was independently conducted and analyzed according to prespecified objectives.

The initial exploratory cohort, PICC-1, was originally planned to enroll 20 eligible patients to receive neoadjuvant toripalimab plus celecoxib or toripalimab alone, with the primary objective of assessing feasibility and safety. The study was amended in August 2020 to change the primary objective to evaluating whether 6 cycles of neoadjuvant toripalimab with or without celecoxib improves the pathological complete response (pCR) rate compared with historical controls, with an updated planned enrollment of 34 eligible patients, who were to be randomized 1:1 between the two treatment groups. In May 2021, an additional 16 eligible patients were included in this exploratory cohort for translational research purposes.

The study was amended in April 2022 to add a new cohort, PICC-2, which was designed to formally compare the efficacy and safety of 12 cycles of neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy in patients with dMMR or MSI-H locally advanced colorectal cancer. A total of 110 eligible patients are planned to be randomized 1:1 between the two treatment groups.

The study was amended in June 2025 to add a new cohort, PICC-3, which was designed to evaluate the 3-year event-free survival (EFS) of 12 cycles of toripalimab plus celecoxib administered as neoadjuvant or definitive therapy in patients with dMMR or MSI-H locally advanced colorectal cancer. Approximately 108 eligible patients are expected to be enrolled.

03

Conditions studied

  • Colorectal Cancer
  • Mismatch Repair-deficient (dMMR)
  • Microsatellite Instability-high (MSI-H)
  • Neoadjuvant Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written .
  2. Histological or cytological documentation of adenocarcinoma of the colon or rectum.
  3. Tumor tissues were identified as mismatch repair-deficient (dMMR) by immunohistochemistry (IHC) method or microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR).
  4. Male or female subjects aged 18 to 75 years.
  5. (ECOG) performance status of 0 or 1.
  6. Determined CT or MRI scans (done within 14 days of registration) of the chest, abdomen and pelvis: locally advanced (cT3-4 or cN1-2 [with the definition of a clinically positive lymph node being any node ≥ 1.0 cm]).
  7. Non complicated primary tumor (obstruction, perforation, bleeding).
  8. No previous any systemic anticancer therapy for colorectal cancer disease.
  9. Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization.
  2. Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment.
  3. Heart failure grade III/IV (-classification).
  4. Unresolved toxicity higher than v.4.0 Grade 1 attributed to any prior therapy/procedure.
  5. Subjects with known allergy to the study drugs or to any of its .
  6. Current or recent (within 4 weeks prior to starting study treatment) treatment of another drug or participation in another investigational study.
  7. Breast- feeding or pregnant women
  8. Lack of effective .
  9. Previously received anti-programmed death-1 () or its ligand (PD-L1) antibody, anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T-lymphocyte-associated Protein 4, CTLA-4) antibody or other drug/antibody that acts on T cell costimulation or checkpoint pathways.
  10. With any distant .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    PICC-1 exploratory cohort

    Neoadjuvant toripalimab with or without celecoxib for 6 cycles

    Drug: Neoadjuvant toripalimab plus celecoxib for 6 cycles · Drug: Neoadjuvant toripalimab monotherapy for 6 cycles

  • Experimental
    PICC-2 cohort

    Neoadjuvant toripalimab with or without celecoxib for 12 cycles

    Drug: Neoadjuvant toripalimab plus celecoxib for 12 cycles · Drug: Neoadjuvant toripalimab monotherapy for 12 cycles

  • Experimental
    PICC-3 cohort

    Toripalimab plus celecoxib as neoadjuvant or definitive therapy

    Drug: Toripalimab plus celecoxib as neoadjuvant or definitive therapy

Interventions

  • DrugNeoadjuvant toripalimab plus celecoxib for 6 cycles

    Drug page: ToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab was administered intravenously over 30 minutes at a dose of 3 mg per kilogram on day 1 of each 14-day cycle, every 2 weeks for a total of 6 cycles, and celecoxib was given orally at 200 mg twice daily from day 1 to day 14 of each cycle, followed by surgery.

    Also known as: Toripalimab, Celecoxib

  • DrugToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab was administered intravenously over 30 minutes at a dose of 3 mg per kilogram on day 1 of each 14-day cycle, every 2 weeks for a total of 6 cycles, followed by surgery.

    Also known as: Toripalimab

  • DrugNeoadjuvant toripalimab plus celecoxib for 12 cycles

    Drug page: ToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab was administered intravenously over 30 minutes at a dose of 3 mg per kilogram on day 1 of each 14-day cycle, every 2 weeks for a total of 12 cycles, and celecoxib was given orally at 200 mg twice daily from day 1 to day 14 of each cycle, followed by surgery.

    Also known as: Toripalimab, Celecoxib

  • DrugToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab was administered intravenously over 30 minutes at a dose of 3 mg per kilogram on day 1 of each 14-day cycle, every 2 weeks for a total of 12 cycles, followed by surgery.

    Also known as: Toripalimab

  • DrugToripalimab plus celecoxib as neoadjuvant or definitive therapy

    Drug page: ToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab was administered intravenously over 30 minutes at a dose of 3 mg per kilogram on day 1 of each 14-day cycle, every 2 weeks for a total of 12 cycles, and celecoxib was given orally at 200 mg twice daily from day 1 to day 14 of each cycle, followed by surgery or non-operative management based on restaging (non-operative management was recommended for patients with a complete clinical response).

    Also known as: Toripalimab, Celecoxib

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rates (PICC-1 and PICC-2 cohorts)

    The proportion of patients who achieved a pCR, which was defined as the absence of residual viable tumor cells in the primary tumor and all sampled lymph nodes at surgery.

    Time frame: 1 year

  2. Event-free survival (EFS) (PICC-3 cohort)

    Defined as the time from randomization until the date of one of the following events (whichever occurred first): disease progression that precluded surgery, local R2 resection, local recurrence after an R0/1 resection, distant metastases, a new primary colorectal cancer, or death from any cause.

    Time frame: 3 years

Secondary outcomes

  1. Overall survival (OS)

    Defined as the time from randomization to death from any cause.

    Time frame: 5 years

  2. R0 resection rates

    The proportion of patients achieved a complete resection with negative margin.

    Time frame: 1 years

  3. Surgical and perioperative treatment safety

    Assessed by evaluation of treatment-related adverse events

    Time frame: 1 years

  4. Surgery feasibility

    Any treatment-related delays in the planned surgery of no more than 28 days after the last preoperative toripalimab dose

    Time frame: 30 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hu H, Shen X, Li Y, Zhou J, Liu P, Zhang J, Hou Y, Wang X, Deng J, Zheng Z, Li J, Lan P, Wu X, Kang L, Huang M, He Z, He X, Yang Z, Huang L, Wang H, Wang H, Luo S, Chen D, Xie X, Zhang Y, Zhai X, Li S, Li W, Hu J, Yang T, Wang C, Deng W, Huang Y, Cao W, Li F, Shi L, Ling L, Deng Y. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2026 Jul 1:S1470-2045(26)00220-2. doi: 10.1016/S1470-2045(26)00220-2. Online ahead of print. PubMed 42385761 ↗
  • Cao W, Hu H, Li J, Wu Q, Shi L, Li B, Zhou J, Wang X, Chen J, Wang C, Wang H, Deng W, Huang Y, Deng Y. China special issue on gastrointestinal tumors-Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD-1 blockade: A post hoc analysis of the PICC phase II trial. Int J Cancer. 2023 Dec 1;153(11):1894-1903. doi: 10.1002/ijc.34647. Epub 2023 Jul 6. PubMed 37409565 ↗
  • Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):38-48. doi: 10.1016/S2468-1253(21)00348-4. Epub 2021 Oct 22. PubMed 34688374 ↗
  • Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 Dec;161(6):1813-1829. doi: 10.1053/j.gastro.2021.09.059. Epub 2021 Oct 2. PubMed 34606846 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Apr 2027, 94 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 94 months is above that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2019
First posted
Apr 24, 2019
StartActual
May 10, 2019
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2030
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03926338
Responsible party
Yanhong Deng (Director of Medical Oncology, Clinical Professor, Sun Yat-sen University) — Principal investigator
First posted
Apr 24, 2019
Start date
May 10, 2019
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Nov 20, 2025

Study contacts

Yanhong Deng, M.D.
Contact
dengyanh@mail.sysu.edu.cn
86-13925106525
Yanhong Deng, M.D.
principal investigator · Sixth Affiliated Hospital, Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Toripalimab

Start the discussion